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Abstract: Clinical trials have consistently shown the beneﬁ  ts of beta-blocker treatment in   
patients with chronic heart failure (HF). As a result, bisoprolol, carvedilol, and metoprolol 
succinate are now indicated for the treatment of all patients with chronic HF who do not have 
major contraindications. Bisoprolol is the ﬁ  rst beta-blocker shown to improve survival in an 
outcome trial. In the Cardiac Insufﬁ  ciency Bisoprolol Study II (CIBIS-II), all-cause mortality 
and sudden death were reduced in patients treated with bisoprolol compared with those on 
placebo (11.8% vs 17.3%; p < 0.0001 and 3.6% vs 6.3%, p < 0.002; respectively) regardless of 
age, NYHA functional class, and co-morbidities. Further studies have shown both the efﬁ  cacy 
of bisoprolol on secondary endpoints and patients subgroups as well its high cost effectiveness. 
More recently, CIBIS-III has shown similar efﬁ  cacy and safety of the initiation of HF treatment 
with either bisoprolol or enalapril, with a tendency to a survival advantage with bisoprolol. 
Nowadays, the role of bisoprolol, as well as that of carvedilol and metoprolol succinate, in HF 
treatment is ﬁ  rmly established and research is mainly focused on implementation of treatment 
and better dosing. This article will summarize evidence for the efﬁ  cacy of bisoprolol in the 
treatment of HF.
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Introduction
Heart failure (HF) is a disease of epidemic proportions. Its prevalence ranges from 
0.4% to 2% in the adult population of Western countries and increases 2- to 3-fold 
when patients with asymptomatic left ventricular (LV) dysfunction and with normal 
LV ejection fraction (EF) are included (Cowie et al 1997; Cleland et al 2001; Stewart 
et al 2001). Despite recent advances, its prognosis remains poor. Half of the patients 
die within 3–5 years after their ﬁ  rst diagnosis and 1-year mortality rate may reach 
50% in patients with severe HF (Cowie et al 1997; Cleland et al 2001; Stewart et al 
2001; Hunt et al 2005; Swedberg et al 2005)
Randomized controlled trials have allowed the selection of therapies able to improve 
quality of life and outcomes in patients with chronic HF. Hence guidelines now rec-
ommend the administration of beta-blockers, angiotensin-converting enzyme (ACE) 
inhibitors, angiotensin receptor blockers (ARBs) and, in New York Heart Association 
(NYHA) class III to IV patients, aldosterone antagonists, to improve prognosis of the 
patients with HF (Hunt et al 2005; Swedberg et al 2005). Diuretics are indicated for 
symptomatic treatment of ﬂ  uid overload when present and manifest as pulmonary 
congestion or peripheral edema. Digoxin is also indicated to improve symptoms in 
patients with NYHA class III and IV HF (Swedberg et al 2005).
Beta-blockers are therefore the mainstay of current medical treatment of HF. 
Bisoprolol was the ﬁ  rst beta-blocker shown to have beneﬁ  cial effects on outcomes Therapeutics and Clinical Risk Management 2007:3(4) 570
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in the Cardiac Insufﬁ  ciency Bisoprolol Study II (CIBIS-II) 
(CIBIS-II Investigators and Committees 1999). The aim of 
this article is to review its main pharmacological character-
istics with respect to its use in the patients with HF.
Pathophysiological mechanisms in HF
The introduction of beta-blockers in the treatment of HF 
has represented a major breakthrough in the treatment and 
interpretation of this syndrome. When HF was considered as a 
hemodynamic disorder, sympathetic activation was regarded 
as a favorable response increasing myocardial contractility 
and cardiac output. However, concomitant studies had shown 
the independent prognostic role of sympathetic activation in 
HF as well its long-term deleterious effects on myocardial 
function and outcome. Increased cardiac sympathetic drive 
was shown to be associated with increased myocardial 
energy expenditure and possibly ischemia of the failing heart. 
Subsequently, beta-1 adrenergic receptors (ARs) stimulation 
was shown to be a powerful mechanism leading to acceler-
ated cell death, through apoptosis (Communal et al 1998), 
and to major changes in the qualitative characteristics of 
myocardial cells with reduced contractility and abnormal 
intracellular calcium handling by the sarcoplasmic reticulum 
(Lowes et al 2002). The role of sympathetic stimulation in 
all these quantitative and qualitative changes in myocardial 
characteristics was indirectly shown by their reversal with 
beta-blocker treatment (Bristow 2000; Metra et al 2000b).
Beta-blocker therapy in HF: 
historical notes
Controlled clinical trials reconciled pathophysiological 
findings, showing the deleterious effects of long-term 
sympathetic activation, with clinical ﬁ  ndings. Relatively 
small, single-center trials showed the beneﬁ  cial effects of 
beta-blockers on clinical symptoms and, to an even greater 
extent, on myocardial function. All the major changes 
associated with LV remodeling: LV dilatation, acquisition 
of a spherical shape, and mitral regurgitation, were reduced 
by the long-term administration of beta-blockers with a 
concomitant, highly significant, improvement in LVEF 
(Bristow 2000; Lechat et al 1998; Metra et al 1994, 2000b, 
2007). The magnitude of these changes is actually greater 
than that described with ACE inhibitors. Randomized con-
trolled trials, having mortality as primary endpoint, showed 
the beneﬁ  cial effects of beta-blockers on mortality and hos-
pitalizations, with reductions in both sudden cardiac deaths 
(SCD), HF deaths, cardiovascular hospitalizations, and HF 
hospitalizations (CIBIS II Investigators and Committees 
1999; MERIT-HF Study Group 1999; Packer et al 2001). 
This has led to the indication for beta-blocker therapy for all 
patients with chronic HF who do not have major contrain-
dications (Hunt et al 2005; McMurray et al 2005; Swedberg 
et al 2005). Based on the results of early post-infarction 
trials as well as of the more recent Carvedilol Post-Infarct 
Survival Control in LV Dysfunction (CAPRICORN) trial 
(The CAPRICORN Investigators 2001), beta-blockers are 
also recommended in patients with LV systolic dysfunction 
following myocardial infarction, regardless of whether they 
are symptomatic or not for HF (Hunt et al 2005; Swedberg 
et al 2005).
Bisoprolol has been extensively studied in the patients 
with chronic HF. In the following sections of this article we 
will describe its main pharamacokinetic and pharmacody-
namic characteristics with respect to the treatment of HF.
Essential clinical pharmacology
Beta-receptor selectivity
Bisoprolol has high selectivity for beta-1 ARs with a beta-1 
to beta-2 antagonist activity ratio of 119. Its selectivity for 
beta-1 ARs is higher compared with metoprolol, the other 
selective beta-blockers used in the treatment of HF (beta-1 
to beta-2 ratio, 45) (Bristow 2000). This high selectivity 
might lead to better tolerability in patients with concomitant 
chronic obstructive pulmonary disease (COPD) as well as 
with peripheral vascular disease (Metra et al 1999; Sirak 
et al 2004; Le Jemtel et al 2007)
Pharmacokinetics
Bisoprolol is almost completely absorbed in the enteric tract 
(90%) with very low liver ﬁ  rst pass metabolism (10%). It has 
low plasma protein binding (30%) with a 1:1 ratio between 
hepatic metabolism and renal excretion. In normal subjects, 
its half-life is long (10–11 hours) and is further prolonged 
in patients with HF (17 ± 5 hours) and/or with severe renal 
failure allowing once-daily administrations (Leopold et al 
1997). Bisoprolol does not interfere with the metabolism 
of other drugs.
Modes of administration
As with all beta-blockers in patients with HF, bisoprolol 
should be started with low doses with gradual (1- to 2-week 
intervals) uptitration to target doses. Treatment is generally 
started with 1.25 mg once daily with subsequent uptitra-
tion to 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, and 10 mg/daily, if 
tolerated (CIBIS-II Investigators and Committees 1999). 
Interestingly, target dose of bisoprolol was 5 mg in the ﬁ  rst Therapeutics and Clinical Risk Management 2007:3(4) 571
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CIBIS trial, in which bisoprolol did not signiﬁ  cantly reduce 
mortality, while it was 10 mg in CIBIS-II, in which bisoprolol 
reduced mortality (CIBIS-II Investigators and Committees 
1994, 1999). Taking into account the differences in the initial 
as well as in the target doses (carvedilol, 3.125 mg bid to 
25–50 mg bid, metoprolol succinate, 12–25 mg to 200 mg 
daily), similar protocols for initiation of therapy and uptitra-
tion must be used also for the other beta-blockers approved 
for HF treatment (Hunt et al 2005; McMurray et al 2005; 
Swedberg et al 2005).
The dose of the beta-blockers may be reduced in case 
of worsening HF or other adverse hemodynamic effects 
(hypotension, bradycardia). This may occur during the 
uptritation phase or, less often, while the patient in on stable 
maintenance doses. Bisoprolol, like any other beta-blocker 
indicated for HF treatment, should be completely withdrawn 
only in case of absolute intolerance. In addition to 
hemodynamic reasons (hypotension, bradycardia), the only 
absolute contraindication to beta-blocker treatment is asthma 
sensitive to the administration of beta-2 ARs agonists (Metra 
et al 1999, 2004; Hunt et al 2005; McMurray et al 2005; 
Swedberg et al 2005). Patients with bronchial asthma may, 
however, show better tolerance to bisoprolol, compared 
with other beta-blockers, because of its greater beta-1 ARs 
selectivity (Metra et al 2004).
Bisoprolol, like all other beta-blockers, should not 
be stopped abruptly as this may cause tachycardia, 
tachyarrhythmias, angina, and worsening HF. If the 
discontinuation is necessary, the dose should be decreased 
gradually.
Effects in the patients with HF
Heart rate (HR)
As expected with beta-blocker treatment, bisoprolol admin-
istration is associated with a reduction in HR. This has been 
consistently shown in CIBIS (–16.3 ± 15.3 vs –1.6 ± 13.4 
bpm with placebo and bisoprolol, respectively; p < 0.001), 
as well as in CIBIS II (–9.8 ± 14.7 vs –0.2 ± 13.7 bpm with 
placebo) (Lechat et al 1997, 2001). In CIBIS, the changes 
in HR were predictive of survival, with a longer survival 
in patients showing the greatest decrease in HR (Lechat 
et al 1997). Similarly, in CIBIS II, both baseline HR and 
its changes after 2 months of treatment were related to sur-
vival (Lechat et al 2001). This analysis also showed that the 
beneﬁ  cial effects of beta-blocker therapy (eg, bisoprolol) 
were independent of the HR changes. Patients on bisoprolol 
had a better survival, compared with those on placebo, both in 
the subgroups of patients with lower or higher HR at baseline 
and in the patients with no change, a decrease, or an increase 
in HR from baseline (Lechat et al 2001).
A recent analysis of data from the carvedilol or meto-
prolol European trial (COMET) conﬁ  rmed these results. 
COMET included 3029 patients with chronic HF randomized 
to carvedilol or metoprolol. In this trial, the HR measured 
at 4 months after the initiation of beta-blocker therapy was 
related to subsequent mortality. However, neither the HR 
before the initiation of beta-blocker therapy nor the changes 
from baseline in HR had any prognostic value (Metra et al 
2005). Beta-blockers counteract the deleterious effects of 
tachycardia in the failing heart so that the HR measured 
before treatment loses its prognostic signiﬁ  cance.
Blood pressure (BP)
In CIBIS-II, bisoprolol reduced BP from baseline (–4.1 ± 16.4 
vs –2.3 ± 16.4 mmHg with placebo for systolic BP, and –2.6 ± 10.7 
vs –0.9 ± 10.9 mm Hg with placebo, p <0.0001 in both cases) (Le-
chat et al 1997, 2001). There was no relation between changes in 
blood pressure and mortality in CIBIS (Lechat et al 1997, 2001). 
Interestingly, a low BP is predictive of increased mortality, rather 
than the opposite, in the patients with HF (Metra et al 2005).
LV function
Bisoprolol is a beta-blocker with high selectivity for beta-1 
ARs. It has no intrinsic sympathomimetic activity and no 
membrane stabilizing activity. Lacking of any ancillary prop-
erty, it may probably be considered as “the purest” beta-1 AR 
blocker for the treatment of HF. Its hemodynamic effects in 
patients with HF were studied in single center trials (Nyolczas 
et al 2000; Dubach et al 2002; Belenkov et al 2003) as well 
as in the two, large, randomized, placebo-controlled outcome 
trials (CIBIS Investigators and Committees 1994; CIBIS-II 
Investigators and Committees 1999). In the study by Dubach 
et al (2002) the effects of bisoprolol on LV function were 
studied by nuclear magnetic resonance myocardial tagging 
in 28 patients with chronic HF randomized to bisoprolol or 
placebo. One-year treatment with bisoprolol was associated 
with an increase in LVEF (from 25 ± 7 to 36 ± 9%; p < 0.05) 
and a non-signiﬁ  cant decline in LV end-diastolic and end-
systolic volumes (–54 and –62 mL, respectively). No change 
occurred with placebo.
An improvement in LV function has been shown also 
with the other beta-blockers having beneﬁ  cial effects on 
mortality in HF (Metra et al 1994; Hall et al 1995; Lechat et al 
1998; Lowes et al 2002). In a randomized comparison study, 
carvedilol has been associated with a greater improvement 
in LVEF, compared with metoprolol tartrate (Metra et al Therapeutics and Clinical Risk Management 2007:3(4) 572
Metra et al 
2000a). However, no comparison study with metoprolol 
succinate, as well as bisoprolol, has been concluded to our 
knowledge.
In a retrospective analysis of CIBIS, the changes in LV 
fractional shortening were related to subsequent prognosis 
both in the bisoprolol and the placebo groups. Patients who 
had a fractional shortening change >0.014 (median value) had 
a better survival than the others. The change in LV fractional 
shortening, the changes in HR, and bisoprolol administration 
were independent predictors of survival (Lechat et al 1997). 
These results were consistent with other studies showing 
that the changes in LVEF after beta-blocker therapy predict 
subsequent outcome (Metra et al 2003).
Neurohormonal parameters 
and inﬂ  ammatory markers
Pousset et al (1996) assessed HR variability (HRV) in 54 
patients enrolled from CIBIS. Patients receiving bisoprolol 
showed an increase in HRV parameters related to para-
sympathetic activity (24-hour rMSSD, p = 0.04; 24-hour 
pNN50, p = 0.04; daytime SDNN, p = 0.05 and daytime 
high-frequency power, p = 0.03). These authors also ana-
lyzed scatterplots of R-R intervals consistently showing an 
increase in parameters related to parasympathetic tone with 
a decrease in parameters related to sympathetic tone (Copie 
et al 1996). All these changes are known to be associated 
with an improvement in prognosis (Metra et al 2006).
Belenkov et al (2003) and colleagues showed that 
bisoprolol treatment can also decrease other neorohormonal 
parameters such as plasma rennin activity (p < 0.05), plasma 
levels of norepinephrine (p < 0.05), angiotensin II, and al-
dosterone (p < 0.05).
Similarly to other beta-blockers, also the administration 
of bisoprolol has been associated with favorable effects on 
markers of inﬂ  ammatory activity (tumor necrosis factor 
[TNF]-alpha, TNF-receptors, interleukins) both in animal 
models and clinical studies (Ohtsuka et al 2001; von Haehling 
et al 2005; Ichihara et al 2006).
Quality of life
Beneﬁ  cial effects on outcome are the main reason why beta-
blocker therapy is now indicated for all the patients with 
HF who do not have major contraindications. However, an 
improvement in symptoms and quality of life remains the 
second important objective of treatment (Hunt et al 2005; 
Swedberg et al 2005). The effects of beta-blockers on these 
endpoints generally remain less signiﬁ  cant (Metra et al 
1998).
In Lechat’s meta-analysis (1998), the effects of beta-
blockers on NYHA class were less signiﬁ  cant, compared 
with those on mortality, hospitalizations, and LVEF, and 
disappeared with the addition or removal of only 1 moder-
ate-size study. Bolger and Al-Nasser (2003) have assessed 
quality of life and parameters related to exercise capacity 
in over 20 controlled trials with carvedilol, metoprolol, or 
bisoprolol administration to patients with HF. For quality of 
life measurements, the effects of beta-blockers were often 
similar to placebo.
In CIBIS 21% of patients in the bisoprolol group 
improved their NYHA class vs 15% of those on placebo 
(p   0.03). The percentage of patients showing deteriora-
tion in their NYHA class was similar between bisoprolol 
and placebo. Importantly, the rate of withdrawal of treat-
ment caused by side-effects was similar in the placebo and 
bisoprolol groups (82 patients, 26%, in the placebo group vs 
75, 23% in the bisoprolol group; NS) (CIBIS Investigators 
and Committees 1994).
Baxter et al (2002) investigated the tolerability of biso-
prolol treatment in elderly patients with CHF. The rate of 
withdrawal from beta-blocker therapy was twice than previ-
ously reported in clinical trials performed in younger patients. 
Quality of life, assessed through a score, was improved after 
bisoprolol, suggesting better perceived health status and a 
reduction in anxiety and depression (Baxter et al 2002).
Outcome
The Cardiac Insufﬁ  ciency Bisoprolol Study (CIBIS) was a 
placebo-controlled, randomized, double-blind, multicenter 
trial assessing the effect of bisoprolol on outcome and its tol-
erability in 641 patients with symptomatic HF (NYHA class 
III or IV) caused by LV systolic dysfunction (LVEF  40%) 
(CIBIS Investigators and Committees 1994). Bisoprolol 
did not signiﬁ  cantly reduce mortality. Sixty-seven deaths 
(20.9%) occurred in the placebo group compared with 53 
deaths (16.6%) in the bisoprolol group (p = 0.22). Beneﬁ  cial 
effects of bisoprolol were found with respect to other 
endpoints. HF hospitalization rate was lower in the patients 
assigned to bisoprolol, compared with placebo (61 vs 90, 
p < 0.01), and NYHA functional classiﬁ  cation improved in 
21% of patients on bisoprolol compared with 15% on placebo 
(p = 0.03). Beta-blocker therapy was well tolerated (CIBIS 
Investigators and Committees 1994).
The CIBIS trial was the ﬁ  rst large-scale trial testing the 
effects of beta-blockade on mortality alone. A few years 
earlier, the Metoprolol Dilated Cardiomyopathy (MDC) trial 
had assessed the effects of metoprolol tartrate on the combined Therapeutics and Clinical Risk Management 2007:3(4) 573
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endpoint of mortality and heart transplantation with similar 
results (Waagstein et al 1993). Both CIBIS and MDC were 
underpowered, with respect of the size pf their study group, to 
detect a meaningful effect on outcome. In CIBIS, the mortality 
of the patients enrolled was much lower than expected (5% 
vs 36%) and this further decreased the power of the study. 
Second, the target dose of bisoprolol in CIBIS (5 mg/day) 
might have been too low to reach adequate beta-blockade 
in a sufﬁ  cient number of patients. In contrast, target dose of 
bisoprolol in CIBIS-II was 10.0 mg and thus higher doses 
were administered during the maintenance phase, with 564 
patients, 42.5%, receiving 10 mg of bisoprolol; 152 (11%) 
receiving 7.5 mg, and 176 (13%) receiving 5.0 mg daily 
(CIBIS-II Investigators and Committees 1999).
CIBIS-II gave an answer to the questions left unresolved 
by the previous trial, namely, the size of the study popula-
tion of CIBIS-II was large enough to detect meaningful 
differences in outcome between patients randomized to 
bisoprolol or placebo. The results of CIBIS-II were conﬁ  rmed 
and expanded by further trials with metoprolol succinate and 
carvedilol having mortality as primary end-point (MERIT-
HF Study Group 1999; Packer et al 2001).
CIBIS-II was a multicenter, double-blind, randomized 
placebo controlled trial enrolling 2647 patients with symp-
tomatic HF (NYHA class III-IV) and a LVEF  35%, on 
standard therapy with diuretic and ACE inhibitors. This 
trial was prematurely stopped, after a mean follow-up of 
1.3 years, for the signiﬁ  cant reduction in mortality in the 
patients randomized to bisoprolol, compared with those on 
placebo. One hundred and ﬁ  fty-six patients (11.8%) died in 
the bisoprolol group, compared with 228 patients (17.3%) 
in the placebo group (p   0.0001). The estimated annual 
mortality rate was 8.8% in the bisoprolol group and 13.2% 
in the placebo group (hazard ratio [HR]; 95% conﬁ  dence 
intervals [CI], 0.66; 0.54–0.81) (CIBIS-II Investigators and 
Committees 1999).
Mortality reduction was mainly caused by a reduction in 
SCD (48 patients on the bisoprolol vs 83 patients on placebo, 
HR; 95% CI, 0.56, 0.39–0.80; p = 0.0011). Pump failure 
deaths were reduced but this result did not reach statistical 
signiﬁ  cance because of the lower number of events (36 vs 
47 patients, HR; 95% CI, 0.74; 0.48–1.14; p = 0.17). This 
ﬁ  nding, as well as the relatively low 1-year mortality of the 
studied patients, is consistent with the enrollment of patients 
with relatively mild HF having SCD as the main cause of 
mortality.
Bisoprolol also had important effects on cardiovascular 
morbidity. All-cause hospitalizations were lower in the 
patients on bisoprolol (440 patients, 33%) compared with 
those on placebo (513 patients, 39%, HR; 95% CI, 0.80, 
0.71– 0.91; p = 0.0006). Hospital admission for worsening 
HF were also reduced in the bisoprolol compared with the 
placebo group (12% vs 18%, HR; 95% CI, 0.64, 0.53–0.79; 
p = 0.0001). Hospitalizations for ventricular arrhythmias and 
hypotension were also reduced by bisoprolol administration. 
In contrast, hospitalizations for bradycardia and, unexpect-
edly, for stroke (31 vs 16, p = 0.04), were more frequent 
in the patients randomized to bisoprolol and hospitaliza-
tions for angina, myocardial infarction, cardiogenic shock, 
and coronary revascularizations were not different in the 
bisoprolol, compared with the placebo group. This ﬁ  nding, 
as well as the increase in the hospitalizations for stroke, is 
rather unexpected and likely related to the relatively small 
number of events. It is, however, consistent with the lower 
effect on vascular events shown by another selective beta-
blocker (metoprolol tartrate), compared with carvedilol, in 
COMET (Remme et al 2007).
Subgroup analyses of CIBIS-II showed that the beneﬁ  cial 
effects of bisoprolol on mortality and hospitalizations were 
independent from cause of HF, HF severity, and bisoprolol 
dose. Patients assuming higher doses of the study drug 
had less severe HF at baseline and showed a reduction in 
mortality of greater magnitude with bisoprolol, compared 
with the patients who could tolerate only low doses (Simon 
et al 2003).
The beneﬁ  cial effects of bisoprolol on outcome were 
maintained also in high risk patients. In spite of their expected 
increase in the overall risk of death and hospitalization, 
patients with diabetes, renal insufﬁ  ciency, NYHA class IV 
symptoms, and the elderly showed a similar reduction in 
mortality and morbidity as the other patients enrolled in 
CIBIS-II. Similarly, also the patients taking either digitalis, 
amiodarone, or aldosterone antagonists as co-medication had 
similar beneﬁ  ts from bisoprolol therapy as patients not on 
these drugs (Erdmann et al 2001).
Lastly, but importantly, CIBIS-II showed the excellent 
tolerability of bisoprolol. These results were in contrast 
with the widely held belief (at the time of the study) that 
beta-blocker therapy is not well tolerated, if not even con-
traindicated, in patients with HF. The number of treatment 
withdrawals was actually the same in the patients on biso-
prolol and on placebo.
A meta-analysis was performed, including the results 
on CIBIS and CIBIS-II, for a total of 3288 patients. It was 
conﬁ  rmed that bisoprolol administration is associated with 
a highly signiﬁ  cant reduction of overall death (p = 0.0003), Therapeutics and Clinical Risk Management 2007:3(4) 574
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cardiovascular death and hospitalizations (p = 0.0001) 
(Leizorovicz et al 2002).
Which drug ﬁ  rst for the treatment 
of heart failure? The CIBIS-III trial
Despite the high signiﬁ  cance of results obtained with beta-
blocker therapy, all the data had been obtained with the 
administration of beta-blockers on top of standard therapy, 
including ACE inhibitors; hence the recent guidelines indi-
cations (Hunt et al 2005; Swedberg et al 2005). However, 
there are reasons to believe that initiation of treatment with 
beta-blockers, rather than ACE inhibitors, may be beneﬁ  cial 
as well. First, sympathetic activation may precede activation 
of the renin-angiotensin system in HF (Francis et al 1990). 
Second, beta-blockers may reduce renin-angiotensin activa-
tion to a greater extent than what achieved by ACE inhibitors 
with respect to sympathetic activation (Campbell et al 2001). 
Third, SCD is the most important cause of death in the early 
course of HF (MERIT-HF Study Group 1999) and beta-
blockers, differently from ACE inhibitors, have a signiﬁ  cant 
effects protective effect on SCD (CIBIS-II Investigators and 
Committees 1999; MERIT-HF Study Group 1999; Bristow 
2000; Packer 2001)
Only two relatively small studies had assessed the effects 
of initiating treatment of HF with beta-blockers, rather than 
ACE inhibitors (Remme et al 2004; Leier 2004; Sliwa et al 
2004). In the carvedilol and ACE inhibitor remodeling mild 
heart failure evaluation (CARMEN) trial, the administration 
of the combination of carvedilol and enalapril was associ-
ated with the greatest reduction in LV end-systolic volume 
whereas treatment with carvedilol alone had a weaker effect 
and enalapril alone had no effect (Remme et al 2004). This 
study was the ﬁ  rst showing the greater beneﬁ  cial effects 
of combined administration of a beta-blocker and an ACE 
inhibitor, compared with either agent alone. The lack of 
effects of enalapril on LV remodeling was, however, some-
how unexpected. It was likely related to the relatively high 
percentage of patients who were on enalapril before entry 
into the study and who might have developed tolerance to 
the effects of ACE inhibition.
The study by Sliwa et al (2004) compared the effects of 
initiating HF treatment with a beta-blocker rather than an ACE 
inhibitor. Its design was therefore very similar to CIBIS-III. 
In the study by Sliwa et al (2004) initiation of therapy with 
a beta-blocker was associated with a greater effect on LVEF 
and volumes. However, this study was not blinded.
The hypothesis of the CIBIS-III trial was that initiation 
of treatment of HF with the beta-1-selective beta-blocker 
bisoprolol (to which enalapril is subsequently added) is as 
effective and safe as a treatment regimen based on the initia-
tion with the ACE inhibitor enalapril (to which bisoprolol 
is subsequently added). Thus, the primary endpoint of the 
study was showing that initiation of therapy with bisoprolol, 
followed by combination therapy with enalapril after 6 
months, was comparable (non-inferior) to initiation of 
therapy with enalapril, followed by combination therapy with 
bisoprolol, after 6 months, with respect to the prevention of 
all-cause death and all-cause hospitalizations (Willenheimer 
et al 2005).
CIBIS-III was an investigator-initiated, multi-center, pro-
spective, randomized, open-label, blinded endpoint evalua-
tion trial with an independent steering committee, data safety 
monitoring board, masked endpoint committee and clinical 
trial data center. The study included patients aged  65 years, 
with mild to moderate HF (NYHA class II to III), low LVEF 
( 35%), and stable clinical conditions in the previous  7 
days. Patients were assigned to initiation of treatment with 
either bisoprolol, titrated at bi-weekly intervals, from 1.25 
to a target dose of 10 mg/day, or enalapril, titrated from 
5 mg/day to a target dose of 20 mg/day. After 6 months 
of monotherapy, combined administration of enalapril and 
bisoprolol was started and therapy was continued for an 
additional 6–18 months. As already pointed out, CIBIS-III 
was designed as a non-inferiority trial of bisoprolol ﬁ  rst treat-
ment vs enalapril ﬁ  rst treatment (Willenheimer et al 2005).
CIBIS-III started in October 2002 and was terminated 
in May 2005 with the inclusion of 1010 patients from 128 
centers from 20 different countries. Follow-up was completed 
for 445/505 patients in the bisoprolol-ﬁ  rst group and 446/505 
patients in the enalapril-ﬁ  rst group. Mean follow-up duration 
was 1.22 ± 0.42 years. Mean patients’ age was 72.4 ± 5.8 years, 
68.9% of patients were males, and mean LVEF was 28.8%.
The trial was successful with respect to its primary 
endpoint, ie, bisoprolol-ﬁ  rst was not inferior to enalapril-
ﬁ  rst treatment. In the intention-to-treat sample, the primary 
endpoint of all-cause deaths or hospitalizations occurred in 
178 patients in the bisoprolol-ﬁ  rst group and 186 patients 
in the enalapril-ﬁ  rst group (absolute difference –1.6%, 95% 
CI, 7.6%–4.4%, HR 0.94; 95% CI 0.77–1.16; non-inferiority 
for bisoprolol-ﬁ  rst vs enalapril-ﬁ  rst treatment, p = 0.019). In 
the per-protocol sample, the primary endpoint was achieved 
in 163 patients in the bisoprolol-ﬁ  rst group and 165 patients 
in enalapril-ﬁ  rst group (absolute difference –0.7%, 95% 
CI –0.66 to 5.1%, HR 0.97%; 95% CI 0.78 to 1.21; non 
inferiority for bisoprolol-ﬁ  rst vs enalapril-ﬁ  rst treatment, p 
= 0.046).Therapeutics and Clinical Risk Management 2007:3(4) 575
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There were 65 deaths in the bisoprolol-ﬁ  rst group, as 
compared with 73 in the enalapril-ﬁ  rst group (HR 0.88; 
95% CI 0.63–1.22; between-group difference, p = 0.44), and 
cardiovascular deaths were not signiﬁ  cantly different in the 
two groups (55 in bisoprolol-ﬁ  rst treatment vs 56 in enalapril-
ﬁ  rst treatment (HR 0.97; 95% CI 0.67–1.40; between-group 
difference, p = 0.86).
One hundred and ﬁ  fty-one patients in the bisoprolol-ﬁ  rst 
group were hospitalized, as compared with 157 in the enala-
pril-ﬁ  rst group (HR 0.95; 95% CI 0.76–1.19; between-group 
difference, p = 0.66). Sixty-three patients in the bisoprolol-
ﬁ  rst group and 51 in the enalapril-ﬁ  rst group had a hospi-
talization for worsening HF (HR 1.25; 95% CI 0.87–1.81; 
between-group difference, p = 0.23). Other analyses regarded 
patients’ follow-up during either the mono-therapy phase 
(ﬁ  rst 6 months) or the ﬁ  rst year since randomization (Wil-
lenheimer et al 2005).
When the results obtained at the end of the monotherapy 
phase (ﬁ  rst 6 months) were analyzed, 109 patients in the 
bisoprolol-ﬁ  rst treatment vs 108 patients in the enalapril-ﬁ  rst 
treatment group reached the primary endpoint (HR 1.02, 
95% CI 0.78–1.33; p = 0.90); 23 vs 32 died (HR 0.72, 95% 
CI 0.42–1.24; p = 0.24); 99 vs 92 were hospitalized (HR 
1.08, 95% CI 0.81–1.43; p = 0.59).
In a post hoc analysis of patients’ outcome during their 
first year from randomization, 155 in the bisoprolol-first 
group vs 165 patients in the enalapril-first group reached 
the primary endpoint (HR 0.94, 95% CI 0.76–1.17, p 
= 0.59) and 42 vs 60 patients died (HR 0.69, 95% CI 
0.46–1.02; p = 0.065).
Another analysis regarded the effects of treatment on 
SCD rate. During the ﬁ  rst 6 months of monotherapy, 8 of 23 
deaths in the bisoprolol-ﬁ  rst group were sudden, compared 
with 16 of 32 in the enalapril-ﬁ  rst group (HR 0.50, p = 0.107). 
During the ﬁ  rst year, 16 of 42 deaths in the bisoprolol-ﬁ  rst 
group were sudden vs 29 of 60 deaths in the enalapril-ﬁ  rst 
group, representing a signiﬁ  cant 46% reduction (HR, 0.54, 
p = 0.049). The incidence of other causes of death was, in 
contrast, similar between the two treatment groups. Alongside 
the early improvement in SCD rates with bisoprolol treat-
ment, there was an increase in early HF hospitalization rates. 
During the ﬁ  rst 6 months, 39 patients in the bisoprolol-ﬁ  rst 
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group vs 25 patients in the enalapril-ﬁ  rst group were hospi-
talized for worsening HF (Willenheimer 2006).
The two different therapeutic strategies were similar with 
respect to the adverse events. The two drugs had similar 
effects on blood pressure either during the mono-therapy 
phase or the phase of concomitant treatment. Bisoprolol, but 
not enalapril, decreased HR, with similar changes during the 
phase of associated therapy.
Subgroup analysis showed no interaction with any 
variable except for LVEF. Amongst the patients with 
LVEF  28% (median value), bisoprolol-ﬁ  rst was signiﬁ  -
cantly better then enalapril-ﬁ  rst treatment (HR 0.61, 95% CI 
0.44–0.85, p = 0.003) whereas an opposite trend was seen 
among the patients with LVEF  28% (HR 1.23, 95% CI 
0.94–1.61, p = 0.13). This interaction was, however, caused 
mainly by differences in non-cardiovascular hospitalizations 
during monotherapy phase.
Differences between the two regimens may have been 
partially related to differences in the percentage of patients 
reaching target doses in the two arms of the trial. A higher 
percentage of patients who were started with bisoprolol 
reached the target dose of 10 mg/day, (69.1%) compared 
with 53.8% of the patients in the enalapril-ﬁ  rst group. Simi-
larly, target dose of 20 mg/day of enalapril was reached in 
76.7% of the enalapril-ﬁ  rst patients, compared with 67.4% 
of the patients in the bisoprolol-ﬁ  rst group (Willenheimer 
et al 2005).
CIBIS III has shown that there is no difference with 
respect to efﬁ  cacy and safety between initiation of treatment 
with either bisoprolol or enalapril in patients with NHYA 
class II or III HF and low LVEF. It also suggested a greater 
beneﬁ  t on mortality and SCD by initiating treatment with 
bisoprolol, rather than enalapril. The main criticism to this 
trial is that it is based on a rather artiﬁ  cial design in which 
patients continue monotherapy for 6 months before receiv-
ing combined therapy. In clinical practice, patients either 
start both treatments simultaneously or, as recommended 
by guidelines (Hunt et al 2005; Swedberg et al 2005), start 
with the ACE inhibitor and then receive combined therapy 
after a short time (Cleland et al 2005; Dickstein 2006; Wil-
lenheimer et al 2006).
Tolerability
Controlled trials have shown that treatment with bisopro-
lol is well tolerated. In CIBIS trials, withdrawal rates for 
lack of tolerance to bisoprolol were similar to placebo. 
Contraindications to bisoprolol initiation are the same as 
with all other beta-blockers and are clearly summarized in 
guidelines. They include sinus bradycardia, atrio-ventricular 
block, bronchial asthma sensitive to beta-agonist administra-
tion (Hunt et al 2005; Swedberg et al 2005; McMurray et al 
2005, Metra et al 1999). A recent episode of HF decompen-
sation is a contraindication to the initiation of bisoprolol 
treatment, although recent data have shown that beta-blockers 
can be initiated during the same hospitalization caused by 
acute HF and this allows higher doses to be reached and 
better long-term outcome (Gattis et al 2004).
Bisoprolol treatment, as well as treatment with any other 
beta-blocker, still needs implementation in clinical practice. 
Beta-blocker therapy is still underused and underdosed. 
Galatius and colleagues showed as bisoprolol mean dose 
after two months attendance in patients with CHF was only 
33% of target dose (3.1 ± 2.6 mg) and 41% at discharge 
compared with 27% of target dose (13.4 ± 14.0 mg) and 32% 
at discharge in carvedilol group. Thirty-nine and 40% of the 
bisoprolol and carvediolol treated patients, respectively, had 
stopped beta-blocker therapy at discharge and only a minority 
reached target dose (Galatius et al 2004).
Conclusions
The past few years have seen a revolution in our attitude 
towards beta-blockers in HF patients. Years ago, these agents 
were contraindicated. Now we know that they are associated 
with a highly signiﬁ  cant reduction in mortality and hospital-
ization rates in patients with HF. This paradigm shift is the 
result of a better understanding of HF pathophysiology and 
of the results of randomized controlled clinical trials. Despite 
the continuous rise in their prescription rates, beta-blockers 
remain underused and underdosed. Education and further 
implementation of guidelines regarding beta-blocker therapy 
are therefore warranted.
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